TEZSPIRE 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/11015
Periodic Safety Update EU Single assessment - 
11/01/2024 
n/a 
PRAC Recommendation - maintenance 
/202306 
tezepelumab 
II/0009/G 
This was an application for a group of variations. 
11/01/2024 
Annex II 
Annex II and the PL have been updated. 
B.I.a.1.j - Change in the manufacturer of AS or of a 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IAIN/0011 
A.5.a - Administrative change - Change in the name 
06/10/2023 
and/or address of a manufacturer/importer 
responsible for batch release 
Annex II and 
PL 
PSUSA/11015
Periodic Safety Update EU Single assessment - 
20/07/2023 
15/09/2023 
SmPC and PL 
Please refer to TEZSPIRE-
/202212 
tezepelumab 
EMEA/H/C/PSUSA/00011015/202212 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
II/0008 
Update of section 4.5 of the SmPC in order to include 
20/07/2023 
15/09/2023 
SmPC 
Update of SmPC section 4.5 to inform healthcare 
information relating to the humoral antibody 
responses induced by the seasonal influenza virus 
based on final results from study VECTOR 
(D5180C00031); this is a multicenter, randomised, 
double-blind, parallel group, placebo-controlled, 
phase IIIb study to evaluate the potential effect of 
tezepelumab on the humoral immune response to 
professionals that in a randomised, double blind, parallel 
group study of 70 patients aged between 12 and 21 years 
with moderate to severe asthma, tezepelumab treatment 
did not affect the humoral antibody responses induced by 
seasonal quadrivalent influenza vaccination. 
For more information, please refer to the Summary of 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
seasonal quadrivalent influenza vaccination in 
adolescent and young adult participants with 
moderate to severe asthma. In addition, the MAH 
took the opportunity to implement editorial changes 
to section 5.1 of the SmPC. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Product Characteristics. 
IB/0007 
B.II.e.5.a.2 - Change in pack size of the finished 
18/04/2023 
15/09/2023 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
II/0004 
Submission of the final report detailing the extended 
30/03/2023 
n/a 
Based on the extended follow-up data from study 
follow-up data from study D5180C00018 
(DESTINATION) listed as a category 3 study in the 
RMP; this is a multicentre, randomised, double-blind, 
placebo-controlled, parallel group, long term 
extension study designed to evaluate the safety and 
efficacy of 210 mg Q4W subcutaneous of 
tezepelumab in adults and adolescents with severe 
uncontrolled asthma for up to 2 continuous years of 
treatment. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0005 
B.II.b.1.a - Replacement or addition of a 
24/01/2023 
n/a 
D5180C00018 (DESTINATION), there was no apparent 
change to the safety profile of tezepelumab. No new safety 
concerns were identified. 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
II/0001 
B.IV.1.c - Change of a measuring or administration 
12/01/2023 
15/09/2023 
SmPC, 
The SmPC Sections 1, 2, 3, 4.2, 6.4, 6.5, 6.6, 8 and 9 of 
device - Addition or replacement of a device which is 
Labelling and 
the SmPC were updated in order to add a new pre-filled 
an integrated part of the primary packaging 
PL 
pen presentation. The Labelling and the PL have been 
updated accordingly. 
IB/0002 
B.II.e.5.a.2 - Change in pack size of the finished 
07/11/2022 
15/09/2023 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
24/10/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
